Effects of cholecystographic agents and sulfobromophthalein on binding of thyroid hormones to serum proteins.
A number of interactions between thyroid hormones and cholecystographic agents have previously been demonstrated. In the present study we show that cholecystographic agents also interfere with the binding of thyroid hormones to serum proteins. A commercial kit (Tri-Tab) was used in which the uptake of labeled hormone from serum by a silicate adsorbent tablet is measured. In the presence of cholecystographic agents or sulfobromophthalein (BSP), the amount of labeled hormone bound to adsorbent increased in a dose-dependent fashion, reflecting displacement from protein-binding sites. The order of potency was BSP greater than ipodate greater than iopanoate greater than tyropanoate. Displacement of hormone was confirmed by a second methodology in which graded amounts of unlabeled T4 were added to the system. This allowed a Scatchard analysis to be performed for binding sites on T4-binding globulin. The cholecystographic agents and BSP caused displacement of the Scatchard slopes, again demonstrating interference with binding to serum protein sites. A method is described in which the change in Scatchard slope produced by an inhibitor is employed to compute the association constant between T4-binding sites on T4-binding globulin and the inhibitors. The values were: BSP, 14.6 X 10(3) M-1; ipodate, 4.7 X 10(3) M-1, iopanoate, 2.2 X 10(3) M-1; and tyropanoate, 0.1 X 10(3) M-1. Because of these relatively low values and the rapidity with which these agents are normally cleared from serum, it seems likely that effects on free hormone levels would be transient and of small magnitude during routine cholecystography. Also, ipodate, in the 1 g/day dose that has been employed experimentally to treat hyperthyroidism, should have a negligible effect on protein binding. On the other hand, when high levels of these compounds are used in experimental settings to study other aspects of thyroid hormone metabolism, changes in protein binding can occur and confound interpretation of results.
D001798:Blood Proteins / Q000378:metabolism*; D003287:Contrast Media / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D007480:Iopanoic Acid / Q000494:pharmacology; D007487:Ipodate / Q000494:pharmacology; D007700:Kinetics; D008297:Male; D011485:Protein Binding / Q000187:drug effects; D013448:Sulfobromophthalein / Q000494:pharmacology*; D013974:Thyroxine / Q000097:blood*; D014284:Triiodothyronine / Q000097:blood*; D014441:Tyropanoate / Q000494:pharmacology
D001798:Blood Proteins; D003287:Contrast Media; D014284:Triiodothyronine; D013448:Sulfobromophthalein; D014441:Tyropanoate; D007487:Ipodate; D007480:Iopanoic Acid; D013974:Thyroxine